Documents & Records
A 2013 document to the FDA describing Theranos's two-phase Walgreens approach and use of conventional commercial analyzers
Describes Theranos's two-phase Walgreens approach and its use of conventional commercial analyzers in a 2013 document to the FDA.
A 2013 document to the FDA describing Theranos's two-phase Walgreens approach and use of conventional commercial analyzers
MentionedFederal Criminal Trial